Clinical trial
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT07594548 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Lead sponsor
- Northwestern University
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 9, 2027
- Completion date
- September 9, 2031
- Enrollment
- 18 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, locally advanced esophageal adenocarcinoma, locally advanced gastric adenocarcinoma, locally advanced gastroesophageal junction adenocarcinoma, metastatic esophageal adenocarcinoma, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, unresectable esophageal adenocarcinoma, unresectable gastric adenocarcinoma, unresectable gastroesophageal junction carcinoma